Jason Rhodes joined Atlas Venture in 2014 as a partner in the life sciences group. Prior to joining Atlas, Jason was President and Chief Financial Officer of Epizyme (NASDAQ: EPZM) from 2010 to 2014, and was instrumental in building the business, including its successful IPO in 2013, follow on financing in 2014 and more than $180 million in funding through partnerships with Celgene, GSK, and Eisai. Prior to Epizyme, Jason was Vice President of Business Development at Alnylam (NASDAQ: ALNY), where he brought in more than $200 million in funding through partnerships with Takeda, GSK, Isis, Cubist, Kyowa Hakko Kirin, and Medtronic as well as the spin out of Regulus Therapeutics (NASDAQ: RGLS). Before joining Epizyme, Jason was a founder and partner with Fidelity Biosciences where he led investments in therapeutics companies, including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer), and Tetraphase (NASDAQ: TTPH). While at Fidelity, he was also acting Chief Business Officer of FORUM Pharmaceuticals. Earlier in his career, Jason was a strategy consultant for biopharma and high tech companies. Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.

Mark Manfredi brings nearly two decades of experience in cancer biology to Raze. Before joining Raze, Dr. Manfredi was Vice President, Oncology Biology at Takeda Pharmaceuticals. Here he was a member of the organization’s senior R&D management team responsible for the global oncology R&D strategy. He led Takeda’s Oncology Biology group, which included functions spanning target identification to preclinical translational research support for development projects.

Prior to that, Dr. Manfredi served as Senior Director at Takeda, leading departments responsible for the scientific strategy for late preclinical and early development projects. During his time at Takeda the Oncology organization put 8 novel mechanisms into the clinic with the most advanced compounds being in phase 3 clinical development. Dr. Manfredi received his BS from the University of Rhode Island and earned his PhD in Biology from Boston College.


Vipin Suri, PhD, brings 14 years of experience in biology, pharmacology and biomarker development to Raze. Prior to joining Raze at its inception in July 2013, Dr. Suri was Director and Head of Pharmacology at Sirtris, a division of GlaxoSmithKline leading pharmacology and biomarker development for modulators of protein deacetylases in a number of disease areas including metabolism, inflammation and neurodegeneration. Dr. Suri started his career at Wyeth (now Pfizer), where he focused on novel small molecule, peptide, nucleic acid, and protein therapeutics for obesity, Type 2 Diabetes, and other metabolic disorders and led a number of teams through preclinical development. Dr. Suri obtained his PhD in Biochemistry at Brandeis University and his MBA at Yale School of Management. Dr. Suri is the author or coauthor/inventor of 49 publications, presentations and patents.

Nello Mainolfi, PhD, brings to Raze several years of experience in leading projects from target identification to IND enabling studies for multiple target classes in the areas of angiogenesis, immunology, inflammation and neurodegeneration. In his previous role as Senior Investigator at the Novartis Institutes for Biomedical Research, Dr. Mainolfi contributed to the identification of more than 10 compounds that have entered preclinical development with the most advanced currently in Phase II clinical trials. He has also successfully led programs where fragment based drug discovery was used as the key strategy to deliver development candidates. Dr. Mainolfi has authored multiple peer-reviewed publications; he is co-inventor on several patents and has written reviews in the areas of synthetic chemistry and drug discovery.

Dr. Mainolfi received his PhD degree in synthetic organic/organometallic chemistry from Imperial College London and completed a postdoctoral fellowship at The Scripps Research Institute in La Jolla, California with Professor K.C. Nicolaou.


Adam Friedman, MD, PhD, co-founder of Raze, has been an Entrepreneur-in-Residence at Atlas Venture since 2010, helping to launch biotechnology companies exploring new areas of biology to alleviate human disease. He has been integral to the launching and building of several Atlas portfolio companies, including RaNA Therapeutics and Ascelegen, among others. A physician-scientist, he received his AB in molecular biology from Princeton University and completed the MD/PhD degree program at Harvard Medical School in the Harvard-MIT Division of Health Sciences and Technology, with graduate work in genetics and cell biology. A licensed Massachusetts physician, Dr. Friedman received training in pediatrics at Boston Children’s Hospital. He has authored multiple peer-reviewed publications in the fields of systems biology, cell signaling, genetics, and cancer biology.